In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis ...

Menveo, a meningococcal vaccine, plays a critical role in controlling the spread of meningitis by offering protection against multiple strains of Neisseria meningitidis, a leading cause of ...

The vaccine is an injectable suspension for intramuscular use that combines components of GSK's two well-established meningococcal vaccines, Bexsero and Menveo. The vaccine's safety, tolerability ...

with a safety profile consistent with Bexsero and Menveo. GSK’s chief scientific officer, Tony Wood, said that the results show the vaccine protects against “the broadest panel of circulating ...

An immunization within the last 10 years for Tetanus/Diphtheria (Td/Tdap). If under the age of 23, a quadrivalent meningococcal conjugate vaccine (MCV4) on or after your 16th birthday. Acceptable ...

The new vaccine is a combination of GSK’s already-approved vaccines Bexsero and Menveo and is designed to protect against meningitis and blood poisoning caused by the A, B, C, W, and Y ...